Poltreg (PTG) Q4 2024 earnings summary

Executive summary

• Focus on developing TREG-based cell therapies for autoimmune diseases, especially type 1 diabetes and multiple sclerosis, with advanced clinical programs and global leadership in long-term safety and efficacy data.

• 2024 marked by significant regulatory milestones, including EMA approval for phase II clinical trial in pre-symptomatic diabetes and expansion of hospital exemption therapy to adults.

• Strategic partnerships and grant funding secured for further R&D, including collaborations with Antion Biosciences and Kinexum Services for US market entry.

Financial highlights

• Revenue from sales dropped to 350k PLN in 2024 from 1,399k PLN in 2023, mainly due to operational transitions and administrative delays.

• Operating costs increased to 24,305k PLN (2023: 20,820k PLN), driven by higher depreciation and utility costs.

• Net loss widened to 18,708k PLN (2023: 13,551k PLN); cash at year-end was 45,655k PLN, down from 65,951k PLN.

• Equity at year-end was 69,234k PLN, representing 68% of total assets.

Outlook and guidance

• Sufficient cash and grant resources to fund ongoing R&D and clinical trials in key indications.

• Strategic goal to secure at least one partnering agreement in 2025 and advance clinical programs in diabetes and multiple sclerosis.

• Expansion into the US market planned, with subsidiary formation and regulatory preparations underway.